"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Neotrace®-4 is a sterile, nonpyrogenic solution of four trace elements for use as an additive for total parenteral nutrition (TPN).
Each mL contains:
|Zinc Sulfate heptahydrate (equivalent to Zinc 1.5 mg)||6.6 mg|
|Cupric Sulfate pentahydrate (equivalent to Copper 0.1 mg)||0.39 mg|
|Manganese Sulfate monohydrate (equivalent to Manganese 25 mcg)||77 mcg|
|Chromic Chloride hexahydrate (equivalent to Chromium 0.85 mcg)||4.36 mcg|
|Water for Injection, USP||q. s.|
Zinc Sulfate is chemically designated ZnSO4, a white crystalline compound freely soluble in water.
Cupric Sulfate is chemically designated CuSO4, a blue crystalline compound very soluble in water.
Manganese Sulfate is chemically designated MnSO4, a pale red, slightly efflorescent compound soluble in water.
Chromic Chloride is chemically designated CrCl3, a greenish compound, soluble in water.
pH (approximately 2.5) adjusted with sulfuric acid.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Neotrace-4 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.